- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Werfen and Seegene Partner for Technology Sharing Initiative
Pending regulatory approval, the two companies will form a new company named NewCo.
Stock.adobe.com
Werfen finalized its agreement with Seegene Inc. to form a partnership as part of a technology sharing initiative.1 The two companies will form a new company, NewCo, in Spain, pending regulatory approval. This company is expected to be formed during the first half of 2025.
Seegene has a technology sharing initiative with the goal of sharing its advanced diagnostic and and data analysis technologies across the globe. Werfen is the first European company to join in the initiative.
In a press release, Werfen CEO Carlos Pascual said, “Over the past decade, our collaboration with Seegene has showcased the significant impact of their syndromic PCR diagnostic tests on healthcare. We are excited to leverage Seegene's unparalleled technology and manufacturing expertise to develop products tailored for the Spanish and Portuguese market, where there is a high demand for rapid product development due to the frequent emergence of new infectious diseases and viral mutations. This partnership with Seegene will enable us to expand our footprint and respond swiftly to any outbreaks.”
In the same press release, Seegene founder and CEO Dr. Jong-Yoon Chun added, “We have high expectations for this NewCo, which will combine Werfen's extensive business experience with Seegene's leading syndromic product development and production capabilities. We will continue to share our technology with leading global companies and countries that are interested in our technology-sharing initiative. Werfen-Seegene will play a pivotal role in accelerating global expansion of our initiative.”
In other news, Seegene recently announced an expansion of its mpox RUO lineup, adding enhanced detection assays for Clade 1, the deadlier and more transmissible version of the virus.2
In a press release from early September, Seegene executive vice president and chief global sales and marketing officer Daniel Shin said, “As the spread of mpox continues unabated, we have developed new RUO assays for detection of viruses causing the mpox to meet the increasing research demand from affected countries. We are committed to actively supporting global efforts to curb the spread of mpox.”
Seegene also recently announced the launch of the Nature Awards MDx Impact Grants, in partnership with Springer Nature.3 The program will provide grants to projects dedicated to developing new tests for huma infectious diseases, and applications will be open until December 2, 2024.
In a press release, Seegene vice president and R&D division head Dr. Jik Young Park said, “We are thrilled to embark on this new phase with Springer Nature. The new programme reflects the strong global interest generated by last year's initiative. We are committed to driving the development and commercialization of innovative syndromic PCR products that will originate from the visionary minds in the global research community."
In the same press release, Springer Nature chief operating officer Marc Spenle added, “By allowing scientists to directly propose their ideas for product development, we anticipate expanding the range of innovation and ensuring that projects meet unmet clinical needs. Springer Nature will leverage its extensive network in the scientific community to foster robust participation and ensure the success of this collaborative program."
Sources
- Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative. Seegene Inc. October 8, 2024. https://www.prnewswire.com/news-releases/seegene-and-werfen-finalize-partnership-agreement-on-technology-sharing-initiative-302269902.html
- Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for Clade 1. Seegene Inc. September 9, 2024. Accessed October 8, 2024. https://www.prnewswire.com/news-releases/seegene-expands-mpox-ruo-product-lineups-with-enhanced-detection-assays-for-clade-1-302242089.html
- Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays. Seegene Inc. September 2, 2024. Accessed October 8, 2024. https://www.prnewswire.com/news-releases/seegene-and-springer-nature-launch-nature-awards-mdx-impact-grants-to-innovate-syndromic-pcr-diagnostic-assays-302235984.html
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
